EP2949315B1 - Vecteur de dilatation avec composant actif - Google Patents

Vecteur de dilatation avec composant actif Download PDF

Info

Publication number
EP2949315B1
EP2949315B1 EP13859508.7A EP13859508A EP2949315B1 EP 2949315 B1 EP2949315 B1 EP 2949315B1 EP 13859508 A EP13859508 A EP 13859508A EP 2949315 B1 EP2949315 B1 EP 2949315B1
Authority
EP
European Patent Office
Prior art keywords
carrier
expansion carrier
expansion
fiber
active ingredients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP13859508.7A
Other languages
German (de)
English (en)
Other versions
EP2949315A4 (fr
EP2949315A1 (fr
Inventor
Mingshi QIU
Xueliang Qiu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harbin OT Pharmaceutical Co Ltd
Original Assignee
Harbin OT Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harbin OT Pharmaceutical Co Ltd filed Critical Harbin OT Pharmaceutical Co Ltd
Priority to SI201331920T priority Critical patent/SI2949315T1/sl
Priority to PL13859508T priority patent/PL2949315T3/pl
Priority to HRP20211257TT priority patent/HRP20211257T1/hr
Publication of EP2949315A1 publication Critical patent/EP2949315A1/fr
Publication of EP2949315A4 publication Critical patent/EP2949315A4/fr
Application granted granted Critical
Publication of EP2949315B1 publication Critical patent/EP2949315B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/15—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
    • A61F13/20—Tampons, e.g. catamenial tampons; Accessories therefor
    • A61F13/2022—Tampons, e.g. catamenial tampons; Accessories therefor characterised by the shape
    • A61F13/2028—Tampons, e.g. catamenial tampons; Accessories therefor characterised by the shape adapted to change of shape after absorption of liquid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/15—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
    • A61F13/20—Tampons, e.g. catamenial tampons; Accessories therefor
    • A61F13/2022—Tampons, e.g. catamenial tampons; Accessories therefor characterised by the shape
    • A61F13/2037—Tampons, e.g. catamenial tampons; Accessories therefor characterised by the shape having grooves or ribs, having a main axis in the radial direction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/15—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
    • A61F13/20—Tampons, e.g. catamenial tampons; Accessories therefor
    • A61F13/2071—Tampons, e.g. catamenial tampons; Accessories therefor characterised by the material or the structure of the outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/15—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
    • A61F13/20—Tampons, e.g. catamenial tampons; Accessories therefor
    • A61F13/2074—Tampons, e.g. catamenial tampons; Accessories therefor impregnated with hydrophobic, hydrophilic, skin enhancers, medicinal etc. substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • This invention belongs to the field of health care and pharmaceuticals and particularly relates to a type of expansion carrier containing active ingredients.
  • the new carrier material with specific swelling properties play an important role in the food and drug industries, in cosmetics, disinfectants, health care products, and medical devices. Various further profitable applications are possible.
  • the common sterile tampon possesses a wide range of applications. It can be used as absorbent medical cotton, disposable sanitary products such as sanitary napkins during menstruation, and tampons combined with suppositories for internal use.
  • US 2003/153864 A1 discloses a disposable device comprising an expandable tampon (6) made of at least one absorbent material and designed to collect and absorb the active liquid dispensed in the intracorporeal cavity, a source of liquid phase including a capsule enclosing a liquid chargeat least the proximal part of which is at least partially surrounded by the expandable tampon, a covering for temporary protection at least partially covering the distal portion of said capsule, and extending longitudinally to an intermediate level of the tampon in such a way as to form in said tampon a proximal plug not covered by said covering, which is at least radially expandable independently from the remaining part of said tampon.
  • US 4 983 163 A discloses an applicator pad, wherein body may be a stretchable, knitted fabric of moisture absorbent textile into which the dried culture of L. acidophilus and/or L. bulgaricus may be incorporated.
  • US 2007/293837 A1 describes a delivery system including a reservoir formed of porous material; a flowable therapeutic formulation contained within the reservoir; and a covering formed of porous material enveloping the reservoir.
  • the reservoir material comprises an assembly of fibers having interfiber spaces defining pores within which the flowable therapeutic formulation is contained, wherein the reservoir comprises relatively coarse and stiff textile fibers.
  • US 2007/141118 A1 discloses a tampon adapted to deliver a therapeutic agent, the tampon comprising: a tampon body having a distal end; and a dosage form affixed to the distal end of the tampon body, the dosage form including a first active layer dispersible by a first mechanism, the active layer including the therapeutic agent, and an attachment layer dispersible by a second mechanism, wherein the first mechanism is different from the second mechanism.
  • US 3 902 493 A1 reports a medicament-bearing catamenial tampon, comprising: a resilient foam corpus having a modulus of compression which allows it to be reformed following insertion to conform to the irregularities of the vaginal wall; and a medicament-bearing hydrophobic non-woven overwrap which is permeable to vaginal fluids.
  • Chinese patent CN02825892 comprises a special tampon for women
  • Chinese patent CN88105466 comprises a swelling cellulose sponge
  • Chinese patent CN200580022237 comprises a controllable intravaginal swelling device
  • Chinese patent CN200680014597 comprises a dual-mode absorption sanitary napkin
  • Chinese patent CN200880101828 comprises a tampon that can swell based on human anthropometric indices.
  • the problems evolving from the "specific carrier with specific swelling- properties ", such as narrow application, simple and crude components, arbitrary swelling sequences, etc., are not completely resolved. Therefore, the invention of a new-type of expansion carrier with active ingredients demonstrates significant progress.
  • the invention provides a new expansion carrier that can be used as disinfectants, drugs, cosmetics, and other products.
  • the carrier can be manufactured as drugs, cosmetics and disinfectant products respectively.
  • an expansion carrier with active ingredients for intravaginal administration characterized in that, the expansion carrier is made of one disappearing fiber, one natural fiber and one synthetic fiber in a ratio of 4-7:1 -3:1, the active ingredients are substances acting as therapeutics, health care, disinfectant, cosmetics, or cleansing products, and immerse into the carrier, dissolve or disperse into the surrounding compound of the carrier, wherein the weight ratio of the active ingredients and the expansion carrier is between 0.1:50 and 50:1, the swelling value of the expansion carrier obtained by melt time assay in the appendix of the Chinese Pharmacopoeia 2010 ed . is from 1-30 when it saturable absorbs water and on the surface of the carrier with active ingredients several ridges are deposed axially or radially or the expansion carrier is coated with a protective layer.
  • This expansion carrier with active ingredients of the present invention can swell in aqueous solution as per the preset swelling value.
  • the administration of the expansion carrier is preferably intravaginal administration. However, the application range should not reduce the scope of protection for this invention.
  • the carried substances including the active ingredients can come in contact with the expansion carrier directly or indirectly.
  • active ingredients include but are not limited to liquor paraffin wax, lanolin, olive oil, carbopol, hyaluronic acid, white mineral oil, lanolin, Vaseline, vegetable oil, water-in-oil (W/O) cleansing cream and lotion, oil-in-water (O/W) cleansing cream and lotion, and surfactant.
  • Disinfection products include but are not limited to chlorhexidine diacetate, chitosan, formic acid, benzoic acid, salicylic acid, ethanol, surfactant, halogens, etc.
  • Drugs include but are not limited to various herbal and mineral medicinal extracts and ornidazole, terconazole, mandelic acid, bismuth subgallate, chlorhexidine diacetate, zedoary turmeric oil, metronidazole, chloramphenicol, sea-buckthorn seed oil, erythromycin, palmatine, flavonoids, furazolidone, policresulen, povidone-iodine, carboprost methylate, Kang Fu Ling, clindamycin phosphate, clotrimazole, matrine, bifonazole, morphine sulfate, sulfasalazine, Callicarpa nudiflora, indometacin and furazolidone, naproxen, diclofenac potassium, pyrantel pamoate, tegafur, tinidazole, ketoconazole, econazole nitrate, b criz, clenbuterol,
  • the 'preset swelling value' of the present invention is achieved by selection and proportion of the materials used for the expansion carrier.
  • the preset swelling values facilitate sufficient contact of the active ingredients with the vaginal epithelium and mucosa, thus achieving selective contact.
  • the preferable materials with a preset swelling value and their proportion are as follows: the first expansion carrier should contain at least one disappearing fiber, one natural fiber and one synthetic fiber. The ratio of the three materials should be 4-7:1 -3:1, most preferably 5.5:2:1. Surprisingly, the expansion carrier can swell according to the preset swelling value in aqueous solution at pH 3.0 - 8.0.
  • the swelling values can differ in different parts of the carrier. Some parts can also have the same swelling value but different swelling sequences.
  • the swelling value of the head part and tail part are identical but the swelling sequence is different.
  • the tail part of the carrier swells first.
  • the whole carrier swells simultaneously.
  • the parts of ridges possess a higher swelling value than the remaining parts.
  • Most preferably the ridge of the tail part possesses the highest swelling value.
  • Head part is the part of the carrier which is inserted into the vagina first.
  • 'Tail part' is the part of the carrier connected to the pull cord which serves for the removal of the carrier from the vagina.
  • the regions with higher swelling values of the expansion carrier are preferably made of cellulose fibers, natural fibers, and synthetic fibers in the ratio of 7:1:1.
  • the regions with lower swelling values are made of cellulose fibers, natural fibers, and synthetic fibers in the ratio of 4:3:1.
  • the two regions can be arranged in various ways, e.g. in intervals or adjacently.
  • S 1 is the mean value of the measured value for the 3 expansion carriers.
  • the swelling value of the carrier according to the present invention preferably ranges from 1 - 10, and a pull cord should be tied to its tail part.
  • the cord can be made from sterile cotton, PVC, PE, nylon, cloth, or other materials.
  • the preferable size of the expansion carrier with active ingredients of the present invention is as follows: the diameter ranges between 3.0 - 15.0 mm, the weight ranges between 1.0 - 4.0 g, the carrier length lies between 10.0 - 60.0 mm, and the cord length is ā‡ 50 mm.
  • the most preferable parameters of the expansion carrier are as follows: the diameter ranges between 10.0 - 11.0 mm, the weight ranges between 2.10 - 2.40 g, the carrier length lies between 43.0 - 46.0 mm, and the cord length is ā‡ 100 mm.
  • the expansion carrier is made of one disappearing fiber, one natural fiber and one synthetic fiber.
  • Synthetic fibers include polyolefin, polyester, polyamide, rayon, high absorbent fiber, polyacrylonitrile fibers, viscose fiber and regenerated cellulose fiber.
  • Natural fibers include wool, cotton, flax, hemp, jute, ramie, and wood pulp.
  • the present invention supplies another preferable technical solution, i.e. the expansion carrier with active ingredients is coated with a protective layer.
  • the protective layer can restrict the swelling degree of the expansion carrier. For example, when a sterile tampon is used as the expansion carrier for loading the active ingredients, the p can be used as the protective layer.
  • an internal expansion carrier can be placed into the expansion carrier with active ingredients of the present invention.
  • the internal expansion carrier swells after the expansion carrier swells.
  • the weight ratio of the active ingredients and the expansion carrier is preferably between 0.1:50 and 50:1. When internal expansion carriers are deposed, the weight ratio of the active ingredient and the sum of carriers is 0.1:50 - 50:1.
  • the disinfectant can be a bacteriostatic and vaginal care agent.
  • the active ingredients include at least one kind of active substance for vaginal cleansing and at least one polymer excipients.
  • the active substances include but are not limited to chlorhexidine acetate and chitosan.
  • the polymer excipients include seaweed polysaccharide and liquid paraffin. The parts by weight of chlorhexidine acetate and chitosan are preferably both 100.
  • the second example is the use as cosmetics.
  • the cosmetics are detergents for vaginal cleansing composed of an expansion carrier with at least one detergent.
  • the cleaning products can further include a booster made from medicinal polyethylene or polypropylene material.
  • the booster is uniform in color.
  • the surface is smooth, without distortions or visible scratches, free from blisters and fatty residues.
  • the preferable detergent is produced from the raw materials with the following parts by weight: liquor paraffin wax 30 - 60 %, lanolin 10 - 40 %, olive oil 10 - 40 %, carbopol 0.01 - 10 %, and hyaluronic acid 0.01 - 10 %.
  • the most preferable detergent has the following composition: liquor paraffin wax 44 %, lanolin 27 %, olive oil 28 %, carbopol 0.5 %, and hyaluronic acid 0.5 %.
  • the beneficial effects of the expansion carrier with active ingredients according to the present invention is its unique swelling performance according to the preset parameters, swelling under specific pH values, timed swelling, which make it as a new expansion carrier possible to be used for drugs, cosmetics, disinfectants and other products.
  • this carrier has a good performance in many different fields. As described in example 1, when it is used as disinfectant the growth inhibition rate of Escherichia coli, Staphylococcus aureus and Candida albicans is 50 % - 90 % after the solution is applied for 3 - 5 minutes.
  • the main body (12) of the expansion carrier (11) with active ingredients of the present invention is made of cellulose fiber, jute and viscose fiber, with a proportion of 5.5:2:1.
  • the cellulose fiber is provided by Shanghai Luoyang New Material Technology Co., Ltd.. several ridges (13) are deposed axially on the surface of the main bady (12).
  • the tail part swells first but has the same swelling value as the head part.
  • a cotton cord (14) is tied to the tail part of the expansion carrier.
  • the active ingredients loaded on the expansion carrier are chlorhexidine acetate and chitosan with a weight ratio of 100: 100, seaweed polysaccharide, and liquor paraffin wax.
  • the growth inhibition rate of Escherichia coli, Staphylococcus aureus and Candida albicans is 50 % - 90 %.
  • the expansion carrier with active ingredients is labeled as 21.
  • Several ridges (23) are deposed axially on the surface of the main body (22).
  • the ridges are the high swelling part, while the other sections are the low swelling part.
  • the high swelling part of the expansion carrier is composed of cellulose fiber, cotton, and viscose fiber in a ratio of 7:1:1.
  • the low swelling part is composed of cellulose fiber, cotton and viscose fiber in a ratio of 4:3:1.
  • the cellulose fiber is provided by Shanghai Luoyang New Material Technology Co., Ltd.
  • the tail part and head part swell simultaneously, but with different swelling values.
  • the active ingredients loaded in the expansion carrier of this example include: liquor paraffin wax 44 %, lanolin 27 %, olive oil 28 %, carbopol 0.5 %, and hyaluronic acid 0.5 %.
  • Figure 3 shows an expansion carrier (31) with active ingredients before swelling, including a sterile tampon (32) wrapped in three non-woven parts (33).
  • a sterile tampon (32) wrapped in three non-woven parts (33).
  • This example is similar to example 1, with the exception that the used material is sterile tampon.
  • the diameter of the most preferable expansion carrier is 10.0 mm; the weight is 2.20 g, the carrier length is 43.0 mm, and the cord length is 150 mm.
  • This example is similar to example 2, with the exception that the used material is a sterile tampon.
  • the diameter of the most preferable expansion carrier is 11.0 mm; the weight is 2.40 g, the carrier length is 46.0 mm, and the cord length is 200 mm.
  • the booster includes a booster main body (63), and a plunger (62) which can slide through the main body, the booster main body (63) is hollow.
  • a handle (64) is deposed on the upper part of the main body (63). The lower part is connected to a sheath (65).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gynecology & Obstetrics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Absorbent Articles And Supports Therefor (AREA)
  • Medicinal Preparation (AREA)
  • Catalysts (AREA)
  • Cosmetics (AREA)

Claims (6)

  1. Un support d'expansion contenant des ingrƩdients actifs pour l'administration intravaginale, caractƩrisƩ en ce que le support d'expansion est fait d'une fibre dissolvante, d'une fibre naturelle et d'une fibre synthƩtique dans un rapport de 4-7:1-3:1, les ingrƩdients actifs sont des substances agissant comme des produits thƩrapeutiques, de soins de santƩ, dƩsinfectants, cosmƩtiques ou de nettoyage et sont immergƩs dans le support, se dissolvent ou se dispersent dans le composƩ environnant du support,
    dans lequel le rapport pondƩral des ingrƩdients actifs et du support d'expansion est compris entre 0,1:50 et 50:1, la valeur de gonflement du support d'expansion dƩcrite par le test de temps de fusion dans l'annexe de la PharmacopƩe chinoise 2010 ed. est de 1 Ơ 30 lorsqu'il absorbe de l'eau Ơ saturation, et
    une pluralitĆ© de nervures (13) sont prĆ©vues axialement ou radialement sur la surface du support avec des ingrĆ©dients actifs, ou le support d'expansion est revĆŖtu d'une couche protectrice.
  2. Le support d'expansion avec des ingrƩdients actifs selon la revendication 1, caractƩrisƩ en ce qu'une corde de traction est fixƩe Ơ la partie d'extrƩmitƩ du support d'expansion.
  3. Le support d'expansion avec des ingrĆ©dients actifs selon la revendication 2, dans lequel le diamĆØtre du support d'expansion est de 3,0 Ć  15,0 mm, le poids est de 1,0 Ć  4,0 g, la longueur du support est de 10,0 Ć  60,0 mm, et la longueur du cordon est de 50 mm, et
    de prĆ©fĆ©rence, le diamĆØtre est de 10,0 Ć  11,0 mm, le poids est de 2,10 Ć  2,40 g, la longueur du support est de 43,0 Ć  46,0 mm et la longueur du cordon est de 100 mm.
  4. Le support d'expansion avec des ingrƩdients actifs selon la revendication 1, dans lesquels les fibres synthƩtiques comprennent la polyolƩfine, le polyester, le polyamide, la rayonne, la fibre hautement absorbante, le polyacrylonitrile, la fibre de viscose et la fibre de cellulose rƩgƩnƩrƩe, et les fibres naturelles comprennent la laine, le coton, le lin, le chanvre, le jute, la ramie et la pulpe de bois.
  5. Le support d'expansion avec des ingrƩdients actifs selon la revendication 4, dans lesquels l'agent d'expansion peut se dilater en solution aqueuse Ơ pH 3,0 - 8,0 selon une valeur de gonflement prƩdƩterminƩe.
  6. Le support d'expansion avec des ingrƩdients actifs selon la revendication 1, dans lequel le support d'expansion est constituƩ d'une fibre dissolvante, d'une fibre naturelle et d'une fibre synthƩtique dans le rapport 5,5:2:1.
EP13859508.7A 2012-11-29 2013-07-16 Vecteur de dilatation avec composant actif Active EP2949315B1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
SI201331920T SI2949315T1 (sl) 2012-11-29 2013-07-16 RazŔiritveni nosilec z aktivno sestavino
PL13859508T PL2949315T3 (pl) 2012-11-29 2013-07-16 Rozszerzalny nośnik ze składnikiem czynnym
HRP20211257TT HRP20211257T1 (hr) 2012-11-29 2013-07-16 Ekspanzivni nosač sa aktivnom komponentom

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201210499627.7A CN102961260B (zh) 2012-11-29 2012-11-29 ę‰æč½½ęœ‰ę•ˆē»„分ēš„č†Øčƒ€č½½ä½“åŠå…¶åŗ”ē”Ø
PCT/CN2013/079450 WO2014082456A1 (fr) 2012-11-29 2013-07-16 Vecteur de dilatation avec composant actif et utilisation associƩe

Publications (3)

Publication Number Publication Date
EP2949315A1 EP2949315A1 (fr) 2015-12-02
EP2949315A4 EP2949315A4 (fr) 2016-07-20
EP2949315B1 true EP2949315B1 (fr) 2021-05-19

Family

ID=47791880

Family Applications (1)

Application Number Title Priority Date Filing Date
EP13859508.7A Active EP2949315B1 (fr) 2012-11-29 2013-07-16 Vecteur de dilatation avec composant actif

Country Status (10)

Country Link
EP (1) EP2949315B1 (fr)
CN (1) CN102961260B (fr)
DK (1) DK2949315T3 (fr)
ES (1) ES2882787T3 (fr)
HR (1) HRP20211257T1 (fr)
HU (1) HUE056363T2 (fr)
PL (1) PL2949315T3 (fr)
PT (1) PT2949315T (fr)
SI (1) SI2949315T1 (fr)
WO (1) WO2014082456A1 (fr)

Families Citing this family (11)

* Cited by examiner, ā€  Cited by third party
Publication number Priority date Publication date Assignee Title
CN102961260B (zh) * 2012-11-29 2014-07-23 哈尔ę»Ø꬧ę›æčÆäøšęœ‰é™å…¬åø ę‰æč½½ęœ‰ę•ˆē»„分ēš„č†Øčƒ€č½½ä½“åŠå…¶åŗ”ē”Ø
CN103181889B (zh) * 2012-11-29 2016-01-13 哈尔ę»Ø꬧ę›æčÆäøšęœ‰é™å…¬åø č†Øčƒ€é˜“é“ę “å‰‚
CN103528474B (zh) * 2013-05-17 2016-03-30 哈尔ę»Ø꬧ę›æčÆäøšęœ‰é™å…¬åø äø€ē§ē”ØäŗŽé˜“道č†Ø胀ꠓēš„ę£€ęµ‹ę–¹ę³•
CN103285133B (zh) * 2013-06-21 2014-10-29 哈尔ę»Ø꬧ę›æčÆäøšęœ‰é™å…¬åø 궈ē³œé˜“道č†Øčƒ€ę “åŠå…¶åˆ¶å¤‡ę–¹ę³•å’Œę£€ęµ‹ę–¹ę³•
CN103316069B (zh) * 2013-06-21 2015-01-28 哈尔ę»Ø꬧ę›æčÆäøšęœ‰é™å…¬åø č‹¦å‚ē¢±ē±»ē”Ÿē‰©ē¢±é˜“道č†Øčƒ€ę “åŠå…¶åˆ¶å¤‡ę–¹ę³•å’Œę£€ęµ‹ę–¹ę³•
CN104161719B (zh) * 2014-08-25 2017-06-16 哈尔ę»Ø꬧ę›æčÆäøšęœ‰é™å…¬åø äø€ē§åˆ†ä½“å¼ę “å‰‚åŠå…¶åˆ¶å¤‡ę–¹ę³•å’Œē”Ø途
CN104434545B (zh) * 2014-11-06 2017-12-12 哈尔ę»Ø꬧ę›æčÆäøšęœ‰é™å…¬åø 化妆品č†Øčƒ€ę “åŠå…¶åˆ¶å¤‡ę–¹ę³•å’Œę£€ęµ‹ę–¹ę³•
CN107088261A (zh) * 2017-04-27 2017-08-25 哈尔ę»Ø꬧ę›æčÆäøšęœ‰é™å…¬åø ē”ØäŗŽé˜“道ēš„č†Øčƒ€ę “ä½“åŠå…¶åŗ”ē”Ø
US20180311151A1 (en) * 2017-04-27 2018-11-01 Mingshi Qui An expandable plug body for use in vagina and its application
CN112250890B (zh) * 2020-10-12 2022-05-13 哈尔ę»Øå·„äøšå¤§å­¦ äø€ē§é™ē½®ę³•åˆ¶å¤‡å£³čšē³–/čŠ³ēŗ¶ēŗ³ē±³ēŗ¤ē»“å¤åˆę°“å‡čƒ¶ēš„ę–¹ę³•
CN112369427A (zh) * 2020-11-13 2021-02-19 南äŗ¬å؁尔å‡Æ勒ē”Ÿē‰©ęŠ€ęœÆęœ‰é™å…¬åø äø€ē§å¹æ谱ꊗē—…ęÆ’ęŠ—čŒę¶ˆęÆ’å‰‚åŠå…¶åˆ¶å¤‡ę–¹ę³•

Family Cites Families (16)

* Cited by examiner, ā€  Cited by third party
Publication number Priority date Publication date Assignee Title
US3902493A (en) * 1974-05-13 1975-09-02 Procter & Gamble Medicated catamenial tampon
US4983163A (en) * 1981-10-09 1991-01-08 Science Research Center, Inc. Method, compositions and articles for prevention and treatment of herpes simplex virus infections
CN2247541Y (zh) * 1996-04-12 1997-02-19 ę±Ÿå«äø– äø€ę¬”ꀧčÆē‰©ę‰æč½½ęŽØčæ›å™Ø
CN1246333A (zh) * 1998-09-02 2000-03-08 å؁廉姆Ā·JĀ·ę³¢ē½—ēŗ³ 聚ē¾§é…øčšåˆē‰©åœØę²»ē–—阓道ꄟꟓäøŠēš„ē”Ø途
US20030153864A1 (en) * 2001-10-16 2003-08-14 Bernard Chaffringeon Disposable device and method for transferring an active liquid into a body cavity
DE10163114B4 (de) * 2001-12-24 2005-03-31 Johnson & Johnson Gmbh Tampon, insbesondere fĆ¼r die Frauenhygiene
CN2613252Y (zh) * 2003-03-26 2004-04-28 安äæ”ēŗ³ē±³ē”Ÿē‰©ē§‘ꊀ(ę·±åœ³)ęœ‰é™å…¬åø ꊗ菌äæå„妇ē”Ø卫ē”Ÿę “
US20070141118A1 (en) * 2005-12-15 2007-06-21 Damico Joyce A Layered dosage form for a medicated tampon assembly
US8137327B2 (en) * 2006-06-16 2012-03-20 Family Health International Vaginal drug delivery system and method
US8597267B2 (en) * 2007-04-18 2013-12-03 The Procter & Gamble Company Tampon having at least one physical discontinuity
CN201030142Y (zh) * 2007-05-22 2008-03-05 ęØ岩 妇ē§‘ē”Øč½½ä½“ę “
CN201591909U (zh) * 2010-02-09 2010-09-29 č“µå·žé•æē”ŸčÆäøšęœ‰é™č“£ä»»å…¬åø äø€ē§ę·±åŗ¦čÆē”Øé˜“é“ę “
CN202497471U (zh) * 2012-02-29 2012-10-24 郑州ē‰§äøšå·„ē؋高ē­‰äø“ē§‘å­¦ę ” åŠØē‰©ē”Ø孕ęæ€ē“ ę£‰ę “
CN202505962U (zh) * 2012-03-30 2012-10-31 äø‡åŽ äø€ē§ę²»ē–—阓道ē‚ŽåŠå®«é¢ˆē³œēƒ‚ēš„ē»™čÆč£…ē½®
CN102961260B (zh) * 2012-11-29 2014-07-23 哈尔ę»Ø꬧ę›æčÆäøšęœ‰é™å…¬åø ę‰æč½½ęœ‰ę•ˆē»„分ēš„č†Øčƒ€č½½ä½“åŠå…¶åŗ”ē”Ø
CN103181889B (zh) * 2012-11-29 2016-01-13 哈尔ę»Ø꬧ę›æčÆäøšęœ‰é™å…¬åø č†Øčƒ€é˜“é“ę “å‰‚

Non-Patent Citations (1)

* Cited by examiner, ā€  Cited by third party
Title
None *

Also Published As

Publication number Publication date
HUE056363T2 (hu) 2022-02-28
EP2949315A4 (fr) 2016-07-20
HRP20211257T1 (hr) 2022-01-07
CN102961260A (zh) 2013-03-13
PT2949315T (pt) 2021-08-12
SI2949315T1 (sl) 2021-10-29
PL2949315T3 (pl) 2021-11-22
DK2949315T3 (da) 2021-08-09
WO2014082456A1 (fr) 2014-06-05
EP2949315A1 (fr) 2015-12-02
CN102961260B (zh) 2014-07-23
ES2882787T3 (es) 2021-12-02

Similar Documents

Publication Publication Date Title
EP2949315B1 (fr) Vecteur de dilatation avec composant actif
AU2002259337B2 (en) Therapeutic agent delivery tampon
US6888043B2 (en) Feminine care products for the delivery of therapeutic substances
US7341737B2 (en) Medicated tampon
AU2002259337A1 (en) Therapeutic agent delivery tampon
WO2003059318A2 (fr) Tampon medicamente
US20030120225A1 (en) Therapeutic agent delivery labial pad
CN104001179A (zh) ę‰æč½½ęœ‰ę•ˆē»„分ēš„č†Øčƒ€č½½ä½“åŠå…¶åŗ”ē”Ø
JPH09124459A (ja) 肛門å‘Øč¾ŗęø…ę‹­ē”Øēµ„ęˆē‰©
US8708947B2 (en) Tampons including moisture-activated compositions
WO2018196040A1 (fr) Corps suppositoire de dilatation pour vagin et son application
AU2003214813B2 (en) Medicated tampon
US20180311151A1 (en) An expandable plug body for use in vagina and its application
JP2001054535A (ja) 궈ęƒē”ØꝐ

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20150528

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20160622

RIC1 Information provided on ipc code assigned before grant

Ipc: A61F 13/20 20060101ALI20160616BHEP

Ipc: A61F 13/32 20060101ALI20160616BHEP

Ipc: A61K 9/02 20060101AFI20160616BHEP

Ipc: A61K 9/00 20060101ALI20160616BHEP

Ipc: A61M 31/00 20060101ALI20160616BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20170901

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20201208

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602013077578

Country of ref document: DE

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1393311

Country of ref document: AT

Kind code of ref document: T

Effective date: 20210615

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: HR

Ref legal event code: TUEP

Ref document number: P20211257T

Country of ref document: HR

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20210806

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Ref document number: 2949315

Country of ref document: PT

Date of ref document: 20210812

Kind code of ref document: T

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20210806

REG Reference to a national code

Ref country code: FI

Ref legal event code: FGE

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG9D

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20210402193

Country of ref document: GR

Effective date: 20210915

REG Reference to a national code

Ref country code: SK

Ref legal event code: T3

Ref document number: E 38062

Country of ref document: SK

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210819

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210519

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20211257T

Country of ref document: HR

Payment date: 20210907

Year of fee payment: 9

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210919

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210519

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210519

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210819

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2882787

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20211202

REG Reference to a national code

Ref country code: HR

Ref legal event code: T1PR

Ref document number: P20211257

Country of ref document: HR

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210519

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210519

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210519

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602013077578

Country of ref document: DE

REG Reference to a national code

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E056363

Country of ref document: HU

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210519

26N No opposition filed

Effective date: 20220222

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210919

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210716

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210519

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20211257

Country of ref document: HR

Payment date: 20220707

Year of fee payment: 10

REG Reference to a national code

Ref country code: AT

Ref legal event code: UEP

Ref document number: 1393311

Country of ref document: AT

Kind code of ref document: T

Effective date: 20210519

REG Reference to a national code

Ref country code: HR

Ref legal event code: PPPP

Ref document number: P20211257

Country of ref document: HR

Owner name: HARBIN BELLEVUE PHARMACEUTICAL CO., LTD., CN

REG Reference to a national code

Ref country code: SK

Ref legal event code: PC4A

Ref document number: E 38062

Country of ref document: SK

Owner name: HARBIN BELLEVUE PHARMACEUTICAL CO., LTD., HARB, CN

Free format text: FORMER OWNER: HARBIN OT PHARMACEUTICAL CO. LTD, HEILONGJIANG, CN; QIU, MINGSHI, HEILONGJIANG, CN

Effective date: 20230427

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210519

REG Reference to a national code

Ref country code: AT

Ref legal event code: PC

Ref document number: 1393311

Country of ref document: AT

Kind code of ref document: T

Owner name: HARBIN BELLEVUE PHARMACEUTICAL CO., LTD., CN

Effective date: 20230530

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20211257

Country of ref document: HR

Payment date: 20230630

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PT

Payment date: 20230629

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20230720

Year of fee payment: 11

Ref country code: HR

Payment date: 20230630

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: TR

Payment date: 20230713

Year of fee payment: 11

Ref country code: IT

Payment date: 20230731

Year of fee payment: 11

Ref country code: IE

Payment date: 20230726

Year of fee payment: 11

Ref country code: GB

Payment date: 20230724

Year of fee payment: 11

Ref country code: FI

Payment date: 20230719

Year of fee payment: 11

Ref country code: ES

Payment date: 20230821

Year of fee payment: 11

Ref country code: CZ

Payment date: 20230707

Year of fee payment: 11

Ref country code: CH

Payment date: 20230801

Year of fee payment: 11

Ref country code: AT

Payment date: 20230718

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SK

Payment date: 20230710

Year of fee payment: 11

Ref country code: SI

Payment date: 20230710

Year of fee payment: 11

Ref country code: SE

Payment date: 20230724

Year of fee payment: 11

Ref country code: PL

Payment date: 20230704

Year of fee payment: 11

Ref country code: HU

Payment date: 20230710

Year of fee payment: 11

Ref country code: GR

Payment date: 20230718

Year of fee payment: 11

Ref country code: FR

Payment date: 20230724

Year of fee payment: 11

Ref country code: DK

Payment date: 20230724

Year of fee payment: 11

Ref country code: DE

Payment date: 20230720

Year of fee payment: 11

Ref country code: BE

Payment date: 20230719

Year of fee payment: 11

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210519

REG Reference to a national code

Ref country code: HU

Ref legal event code: GB9C

Owner name: HARBIN BELLEVUE PHARMACEUTICAL CO., LTD., CN

Free format text: FORMER OWNER(S): HARBIN OT PHARMACEUTICAL CO. LTD, CN; QIU, MINGSHI, CN

Ref country code: HU

Ref legal event code: FH1C

Free format text: FORMER REPRESENTATIVE(S): SBGK SZABADALMI UEGYVIVOEI IRODA, HU

Representative=s name: SBGK SZABADALMI UEGYVIVOEI IRODA, HU